Table of Contents
BERWYN, Pa. — Amring Pharmaceuticals announced its intent to change its name to Nordic Pharma, Inc. The new name takes effect on March 1, 2024. Following the change in the ownership of their company from Sever Life Sciences, B.V. to Nordic Group, B.V. on June 1, 2023, the change in the corporate name provides for better alignment strategically with their parent company headquartered in the Netherlands and its subsidiaries worldwide. Together, the companies look to expand the global footprint in Eye Care, Rheumatology, Woman’s Health and Critical Care for branded products as well as strengthening their generic product business in the U.S.
“There will be no changes other than effective March 1, 2024, Amring will officially become Nordic Pharma, Inc. All current transactional business will remain the same (orders, shipments, returns, accounts payable, etc.). Amring Sales will be attending the ECRM meeting in New Orleans from February 25-29th, 2024 where we will be able to share further details or answer any questions you may have. If you are not attending the ECRM meeting, please feel free to reach out directly to your Amring representative to have your questions addressed. It is understood that there may be some contract and other paperwork that may need to be done, but as of today and after March 1st, our day-to- day business relationship remains the same.
These are exciting times for Amring, with the recent acquisition of Visant Medical, Inc., the forthcoming launch of LACRIFILL canalicular gel, and this new alignment with Nordic Group and its subsidiaries, Amring is poised to grow and expand with you as a key partner today and in the future. Thank you as always for your continued partnership and support as we work to transform into our new brand, Nordic Pharma, Inc.,” wrote Philip Gioia, president and Thomas Sammler, vice president, Commercial Operations in a company memo.
